Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (RAVEN)
Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Fas
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
California
-
Huntington Beach, California, Förenta staterna, 92647
- South Coast Retina
-
Long Beach, California, Förenta staterna, 90807
- South Coast Retina
-
Santa Monica, California, Förenta staterna, 90404
- Thomas Hanscom AMC
-
Torrance, California, Förenta staterna, 90505
- South Coast Retina
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age > 18 years
- CRVO or BRVO diagnosis
- For CRVO, clinical evidence of perfused central retinal vein occlusion. A CRVO is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head.
- Central macular edema present on clinical examination and OCT testing with a central point thickness and/or central 1mm subfield thickness > 300 microns after at least 3 months of bevacizumab or steroid therapy.
- Visual acuity score greater than or equal to 19 letters (20/400) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol.
- Patients must demonstrate that they are no longer improving on bevacizumab or intravitreal steroid therapy (i.e. no improvement in acuity in 2 consecutive visits)
- BRVO patients treated with grid laser must show residual edema three months following latest laser treatment
- Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography
Exclusion Criteria:
- Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.
- Participation in another ocular investigation or trial simultaneously
- Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse)
- Significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy
- An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or geographic atrophy or severe epiretinal membrane)
- Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)
- Evidence of neovascularization of the iris or retina (presence of ischemic CRVO/BRVO)
- Evidence of central atrophy or fibrosis in the study eye
- Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.
- History of grid/focal laser or panretinal laser in the study eye in the previous three months
- History of vitreous surgery in the study eye
- History of use of intravitreal, peribulbar, or retrobulbar steroids within three months of the study.
- History of cataract surgery within 6 months of enrollment.
- History of YAG capsulotomy within 2 months of the surgery.
- Visual acuity <20/400 in the fellow eye
- Uncontrolled glaucoma (pressure >30) despite treatment with glaucoma medications.
- History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: intravitreal ranibizumab 0.5mg
|
Standard dose
Andra namn:
|
|
Experimentell: intravitreal ranibizumab 1.0mg
|
High dose
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Mean Change From Baseline BCVA
Tidsram: Baseline to month 6
|
Vision was measured using a standard ETDRS chart at baseline and each subsequent monthly visit.
|
Baseline to month 6
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Mean Change From Baseline in Center Point Thickness
Tidsram: months 1-12
|
months 1-12
|
|
Change in Mean Best Corrected Visual Acuity From Baseline
Tidsram: months 1-12
|
months 1-12
|
|
Percentage of Patients With CFT Less Than 300um
Tidsram: Month 6 and 12
|
Month 6 and 12
|
|
Excess Foveal Thickness
Tidsram: Month 6 and 12
|
Month 6 and 12
|
|
Total Number of Ranibizumab Injections
Tidsram: month 12
|
month 12
|
Samarbetspartners och utredare
Sponsor
Sponsor
Samarbetspartners
Samarbetspartners
Utredare
Utredare
- Huvudutredare: Thomas O'Hearn, MD, Thomas Hanscom AMC
Studieavstämningsdatum
Studera stora datum
Studiestart
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Faktisk)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Ögonsjukdomar
- Retinal degeneration
- Näthinnesjukdomar
- Embolism och trombos
- Venös trombos
- Trombos
- Makuladegeneration
- Makulaödem
- Retinal venocklusion
- Ödem
- Läkemedels fysiologiska effekter
- Antineoplastiska medel
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Ranibizumab
Andra studie-ID-nummer
Andra studie-ID-nummer
- ML27847
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .